comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 21:05:50 - browse：31273

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： What should King Charles tell the public about his cancer?

focus

WSS

ASCO: Palliative care found as helpful given virtually as in person

Biden report: The neurospychology of memory and aging

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Doctors' information doesn't help them choose wisely when sick

See how much Covid

NIH documents show early flaws of $1.6 billion long Covid program

hotspot

comprehensive

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: How biotech is using artificial intelligence

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How digital tools helped lower hypertension in marginalized patients

Guidelines to prevent youth baseball injuries need more muscle

Gilead might be held responsible for not developing a drug

How one medical school became remarkably diverse

Let's speed up science by embracing open access publishing

hotspot

Woman returns to dialysis after doctors remove transplanted pig kidney

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

PhRMA lawsuit over Medicare drug price negotiation tossed

At ASCO, AstraZeneca reports strong data for breast cancer drug

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare threatens to cut off funding for HCA's Mission hospital

focus

focus

hotspot

entertainment